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Peptide-major histocompatibility complex (p-MHC) class I tetramer complexes have facilitated the early detection
and functional characterisation of epitope specific CD8+ cytotoxic T lymphocytes (CTL). Here, we report on the
generation of seven recombinant bovine leukocyte antigens (BoLA) and recombinant bovine β2-microglobulin from
which p-MHC class I tetramers can be derived in ~48 h. We validated a set of p-MHC class I tetramers against a
panel of CTL lines specific to seven epitopes on five different antigens of Theileria parva, a protozoan pathogen
causing the lethal bovine disease East Coast fever. One of the p-MHC class I tetramers was tested in ex vivo assays
and we detected T. parva specific CTL in peripheral blood of cattle at day 15-17 post-immunization with a live parasite
vaccine. The algorithm NetMHCpan predicted alternative epitope sequences for some of the T. parva CTL epitopes.
Using an ELISA assay to measure peptide-BoLA monomer formation and p-MHC class I tetramers of new specificity, we
demonstrate that a predicted alternative epitope Tp229-37 rather than the previously reported Tp227-37 epitope is the
correct Tp2 epitope presented by BoLA-6*04101. We also verified the prediction by NetMHCpan that the Tp587-95
epitope reported as BoLA-T5 restricted can also be presented by BoLA-1*02301, a molecule similar in sequence to
BoLA-T5. In addition, Tp587-95 specific bovine CTL were simultaneously stained by Tp5-BoLA-1*02301 and Tp5-BoLA-T5
tetramers suggesting that one T cell receptor can bind to two different BoLA MHC class I molecules presenting the
Tp587-95 epitope and that these BoLA molecules fall into a single functional supertype.Introduction
CD8+ cytotoxic T lymphocytes (CTL) play a significant
role in controlling intracellular pathogens such as viruses
and parasites through a perforin/granule mediated cytolytic
mechanism, Fas-induced apoptosis or by release of IFN-γ
[1]. The specificity of CTL is mediated by their T-cell
receptor (TCR) which recognize foreign peptide epitopes
associated with major histocompatibility complex (MHC)
class I molecules at the surface of infected cells (reviewed
in [2]). The antigen specificity of CTL is commonly mea-
sured using synthetic peptide epitopes in IFN-γ ELISpot or
cytolytic assays. However, the demonstration that soluble* Correspondence: n.svitek@cgiar.org; v.nene@cgiar.org
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TCR has led to generation of multimeric forms of p-MHC
class I tetramers as diagnostic reagents that can be used to
detect and purify epitope specific CTL. The importance of
these reagents in research is highlighted by the creation of
a NIH Tetramer Core Facility, which provides to the scien-
tific community pre-made and made-to-order p-MHC
class I tetramers for a number of human, mouse, macaque
and chimpanzee MHC alleles, including class I, class II and
non-classical MHC molecules. Many p-MHC class I tetra-
mers are now also commercially available. However, such
tools are in general not available for livestock species.
Peptide-MHC class I complexes are hetero-trimeric in
nature consisting of the MHC class I molecule, often
referred to as the heavy chain (HC), a peptide of eight to
eleven amino acids in length and an invariant moleculetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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eration of the p-MHC class I complex in vivo involves
many steps and is tightly regulated by chaperones [5].
Peptides are generated by the proteasome, a multi-
catalytic complex in the cytoplasm that cleaves proteins
into polypeptides [6], which are further processed by
ER-luminal peptidases [7] during peptide loading onto
MHC class I molecules by the peptide-loading-complex
[8] prior to export to the cell surface. However, it is pos-
sible to generate p-MHC class I complexes at high effi-
ciency in vitro [9-13] by co-incubation of recombinant
MHC class I HC, synthetic peptide and recombinant
β2m. The affinity of peptides that bind to the peptide-
binding groove in the α1 − α2 domain of the HC is pri-
marily dictated by the identity of amino acids at “anchor
positions” and sequence motifs describe peptides that fit
into a particular peptide-binding groove [14]. Sequence
polymorphisms in this region of the HC result in different
peptide binding specificities and motifs, which mediate
the functional differences between different MHC class I
molecules [15]. These observations have led to the gener-
ation of several algorithms ([16-18], for a detailed review
see [19]) that attempt to predict the presence of CTL
epitopes in proteins.
Different methods have been developed for generating
multimeric peptide MHC complexes [13,20,21]. Here we
describe the use of the system of Leisner et al. [11] for
production of bovine leukocyte antigen (BoLA) p-MHC
class I tetramers to facilitate the study of immune bovine
CTL as part of our subunit vaccine development program
against East Coast fever (ECF), a lethal disease of cattle
in sub-Saharan Africa. The disease kills about one million
animals each year with severe negative socio-economic
impact on the smallholder farmers and pastoralists whose
livelihoods depend on their animals [22,23]. Animals that
recover from infection are solidly immune to re-infection
and this observation led to development of a live parasite
based infection and treatment method (ITM) of vaccin-
ation against ECF [24]. The immunity induced by ITM is
primarily dependent on parasite-specific CTL and is para-
site strain specific. Vaccination with mixtures of parasite
broadens the spectrum of immunity [24,25] and such a vac-
cine, called the Muguga cocktail, which consists of three
different parasite isolates, is available on a commercial basis
in some countries [26]. However, there are several problems
with the live vaccine as it requires a liquid nitrogen cold
chain for delivery, oxy-tetracycline treatment and is expen-
sive ($8 ~ 12/dose). Hence, the availability of a subunit vac-
cine with a better product profile than the current vaccine
is likely to benefit programs targeting the control of ECF.
A feature of the protective CTL response generated by
ITM is that it is focused on a limited number of epitopes,
the identity of which is influenced by the BoLA genotype
of individual animals and the strains of the parasite usedfor immunisation [27]. The antigen and epitope specificity
of CTL induced by the Muguga isolate of T. parva and
restricted by ten different BoLA class I molecules in cattle
has been reported [28,29], and unpublished data]. Identifi-
cation of these T. parva CTL epitopes was carried out in a
two stage process, first through screening of parasite cDNA
to define relevant antigens and then through screening of
synthetic overlapping peptides to define epitopes within the
predicted antigen sequence [29]. Although 12 CTL epitope
sequences were defined they were primarily evaluated in
IFN-γ ELISpot assays and most were not subjected to sys-
tematic analyses to determine minimal epitope sequences.
We previously evaluated NetMHCpan, a pan-predictor of
CTL epitopes to assess the T. parva epitopes. In general we
found that the predictive power of the algorithm for the
known CTL epitopes was high, although the method in
some cases predicted the presence of alternative epitope
sequences of stronger affinity [30].
Here we report on generation of p-MHC class I tetramers
based on a set of seven different recombinant BoLA MHC
class I molecules for detection of CTL responses to epi-
topes located in five different T. parva antigens and the use
of one p-MHC class I tetramer in ex vivo assays. A critical
feature of the Leisner system is that new p-MHC class I
tetramers can be made on demand with a turnaround time
of ~48 h, which as described herein accelerates the ability
to test candidate epitopes and define new CTL specificities.
Based on predictions from NetMHCpan and MHCcluster
we provide experimental evidence that redefines a CTL epi-
tope on antigen Tp2 and that an epitope on antigen Tp5
can be presented by two closely related but distinct BoLA
MHC class I molecules.
Material and methods
Expression and purification of BoLA class I HC and
β2m molecules
The expression and purification of biotinylated BoLA class
I HC molecules was performed essentially as described in
[11]. Briefly, truncated versions of the BoLA class I HC
without their trans-membrane domain and containing a bi-
otinylation tag (BSP) were cloned into pET28a+. The pro-
teins were expressed in E. coli BL21 (DE3) co-transformed
with a pASYC vector encoding the BirA enzyme, which
increases the efficiency of biotinylation of the BSP tag.
Expression of HC and BirA was induced by adding IPTG
(1 mM) during the last 3 h of culture. Biotin (Sigma,
100 mg/L) was added to the culture prior to inducing pro-
tein expression. Large-scale production and purification
were performed as previously described [31]. Briefly, this
involves culture of E. coli BL21 (DE3) in ECPM 1 media
[32] using 2-L Labfors fermenters (Infors AG). Cell lysis
was performed by high-pressure cell disruption (Z PLUS,
Constant Systems, Daventry, UK). Inclusion bodies were
collected by centrifugation at 17 000 g for 10 min at 4 °C.
Table 1 List of bovine immunological reagents
Restricting BoLA
class I molecule
CTL Lines T. parva
antigen
CTL Epitope
1) 6*01301 BB007 & BV115 Tp1 214VGYPKVKEEML224
2) 6*04101 BW02 (Clones 5 & 7) Tp2 27SHEELKKLGML37
3) 2*01201 592 Tp2 49KSSHGMGKVGK59
4) BoLA-T2c Bx196 Tp2 96FAQSLVCVL104
5) BoLA-T5 BV50 Tp5 87SKADVIAKY95
6) 3*00101 Bx63 Tp8 379CGAELNHFL387
7) 1*02301 495 Tp9 67AKFPGMKKSK76
The Table lists the BoLA class I molecules that were expressed in this study,
the panel of CTL lines used to test p-MHC class I tetramers and their antigen
and epitope specificity. The bulk CTL lines were prepared from cattle immunized
with a live parasite vaccine as previously described [29]. The peptide specificity of
each CTL line was confirmed by ELISpot assay (data not shown).
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HCl (pH 8.0) and 8 M urea. HC molecules were purified in
8 M Urea first on Q-Sepharose (Amersham Biosciences)
then on phenyl-Sepharose column (Amersham Biosci-
ences) and high molecular complex aggregates were re-
moved by size exclusion chromatography on Sephacryl
columns. Bovine β2m molecule was purified using the
same method as for human and porcine β2m [31,33,34].
Briefly, recombinant bovine Met-β2m was dissolved in
8 M urea and purified on Q-Sepharose; refolded overnight
by drop-wise dilution into 25 mM Tris, 300 mM Urea,
pH 8; concentrated by tangential flow ultrafiltration
(Vivaflow); and buffer-exchanged into PBS by gel filtration
(Superdex 200, Amersham Biosciences). Finally, the prod-
uct was concentrated and frozen at −20 °C until use.
Production of peptide-MHC class I tetramers
Peptide-MHC class I tetramers were generated as de-
scribed previously [11]. Briefly, purified BoLA HC at a
final concentration of 0.25 μM was incubated with the fol-
lowing: β2m [1.5 μM], peptide [4 μM], EDTA (1 mM),
pepstatin A (1 μM), 1.10 phenantroline (100 μM), TLCK
(50 μg/mL), TPCK (100 μM), PMSF (100 μM), Lutrol
(0.03%), 50 mM of Tris-maleate (pH6.6), in a final volume
of 500 μL. Incubation was performed at 18 °C for 48 h and
then high molecular weight complexes were removed by
centrifugation with an Amicon® Ultra Centrifugal Filter
Units (0.5 mL/100 K) [cat no. UFC510024] at 14 000 g for
10 min. The flow through was recovered and the p-MHC
class I complexes were tetramerized at room temperature
by incubating them with 1.5 μg of phycoerythrin (PE)-
streptavidin (BD Pharmingen, cat no. 554061) or allophy-
cocyanin (APC)-streptavidin (BD Pharmingen, cat no.
554067) starting with 0.45 μg and then adding 0.21 μg
every ten min over a 50 min period at room temperature
and then stored at 4 °C.
Synthetic peptides
Peptides were purchased from Mimotopes (Victoria,
Australia) at a purity of 95% and re-suspended in water
containing 0.1% acetic acid at a final concentration of
10 mM and diluted to working concentrations in sterile
water. The sequences of T. parva peptide epitopes are as
in Table 1. A control known peptide sequence that binds
to BoLA-6*01301, YMYRVWSPL, was determined from a
bank of random nonamer peptides by a binding assay as
described in [34]. The sequence of the control peptide for
BoLA-3*00101 is the Tp4 CTL epitope (TGASIQTTL)
which is a known binder to BoLA-3*00101 [29].
ELISA assay to measure peptide-MHC class I monomer
formation
Folding of p-MHC class I complexes was assessed with
an ELISA assay as described in [35]. The BoLA-6*04101molecules [0.25 μM] and bovine β2m molecule [1.5 μM]
was incubated in a 96-well plate with Tp227-37 and
Tp229-37 peptides at various peptide concentrations
ranging from 0 to 40 μM. After an incubation of 48 h at
18 °C, the complexes were transferred to another 96-well
plate pre-coated with streptavidin (Nunc, cat# 436014),
which captures biotinylated HC, and incubated for three
hours at 4 °C. After washing, the W6/32 monoclonal anti-
body (Santa Cruz Biotechnology, Texas, USA,, cat # SC-
32235), which binds to a monomorphic epitope on β2m
but only when it is incorporated in p-MHC class I com-
plexes, was added for 1 h at 4 °C. After washing, anti-mouse
IgG coupled to peroxidase (Sigma Aldrich, cat # A9917-
1ML) was added to the plate followed by incubation for an
hour at room temperature and further rounds of washes.
Colorimetric change was performed by adding the TMB
Plus2 “Ready to Use” Substrate (Kem En Tec, cat # 4395H)
for 10 min at room temperature. The reaction was stopped
by adding H2SO4 (0.3 M) and optical density was measured
using an ELISA plate reader at 450 nm. The concentration
of MHC class I and β2m molecules used in such assays is
normally in the nanomolar range [35]. However, the bovine
β2m molecule used in this assay contains an extra methio-
nine at the N-terminus that diminishes binding of the W6/
32 antibody to the mature p-MHC class I complex, hence
higher concentrations of recombinant molecules were used
in the assay. We are in the process of generating a β2m
without the extra start methionine, which should allow use
of recombinant molecules in the nanomolar range.
Bovine CTL and parasite-infected cell lines
CTL and autologous T. parva Muguga infected lympho-
cyte lines (TpM) were established as previously described
[29] and maintained in RPMI containing 10% fetal bovine
serum [FBS] (decomplemented; Sigma), 1% penicillin/
streptomycin, 1% L-Glutamine, 1% gentamycin, 0.1% beta-
mercaptoethanol. CTL lines (Table 1) were propagated by
stimulating them with irradiated autologous TpM at a ratio
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with 2 ng/mL of recombinant human interleukin (IL)-2
(Sigma) or 15% T-cell growth factor (TCGF). Cells were
incubated at 37 °C in a 5% CO2 humidified atmosphere.
Clones 5 and 7 of the BW02 CTL line were obtained by
limiting dilution.
ELISpot assays
IFNγ ELISpot assays were conducted as described in
[36]. Briefly, a monoclonal anti-bovine IFNγ antibody
(Serotec, Oxford, UK, cat.no. MCA1783) was incubated
overnight at 4 °C on ELISpot plates (Millipore, Billerica,
MA, USA) and then blocked with RPMI containing 10%
heat-inactivated FBS for 2 h at 37 °C. Peptides were
added at 1 μM concentration and CTL lines at 2.5 × 104
cells per well. The plates were incubated at 37 °C for
20 h. Release of IFNγ was monitored with primary rabbit
polyclonal anti-bovine IFNγ antibody (Sigma–Aldrich, St.
Louis, MO, USA) and secondary AP-conjugated monoclo-
nal anti-rabbit antibody (Sigma–Aldrich, St. Louis, MO,
USA, cat # A2556). Development of plates was done by
addition of the substrate solution Sigma Fast (BCIP/NBT,
Sigma–Aldrich, St. Louis, MO, USA).
Flow cytometry
Flow cytometry data were acquired on a BD FACSCanto™
II instrument (BD Biosciences). Compensation controls
for PE, PerCP, FITC and APC were included for automatic
compensation by the FACS DIVA software. 10 μL BoLA
class I tetramer was used for staining cells (between 2 ×
105 and 5 × 105 cells per sample). CD8 staining was done
by incubating cells with ILRI monoclonal antibody ILA51
(IgG1) and using rat anti-mouse IgG1-PerCP (BD; cat #
340272) as the secondary antibody. Staining for perforin
was done using anti-human-perforin-FITC (BD Pharmin-
gen, San diego, CA, USA, cat# 556577) and staining for
Fas-ligand was done using primary rabbit anti-Fas ligand
(Santa Cruz biotechnology, cat no. SC-957) and secondary
FITC-coupled anti-rabbit IgG antibody (Sigma, MO, USA,
cat# F-0382). All staining were conducted in PBS-0.5%
BSA except for intracellular staining with anti-perforin
where cells were incubated and stained in PBS-0.1%Sap-
onin-10% FBS. Negative control for intracellular staining
was done with anti-dansyl-FITC antibody (BD Pharmin-
gen, San diego, CA, USA, cat# 556577). The data were
analyzed using the FlowJo software version 7.6.5.
Animal experiments
Three cattle of BoLA-A18 haplotype (typed with PCR
primers [forward] 5’-CCGGGATCCGAGGACT-3’ and
[reverse] 5’-CTCCATCTTGCGTTTGGA-3’ specific for
BoLA-6*01301) were vaccinated by ITM [24] using the
T. parva strain Muguga 3308. Whole blood was col-
lected from these cattle at the day of vaccination (day 0)and every two days till appearance of tetramer positive
cells. PBMC were purified on Ficoll paque density gradi-
ents at 2500 rpm for 25 min and 5 × 105 PBMC were
stained with the Tp1214-224-BoLA-6*01301 tetramer as
described in the flow cytometry procedure. This animal
experiment was approved by the ILRI IACUC committee
[# 2012.10].
NetMHCpan and MHCcluster
We used NetMHCpan [37], a pan-specific predictor
trained on known peptide epitope and MHC class I se-
quence data and the affinity of p-MHC class I interac-
tions to predict T. parva epitopes. The binding affinity
of selected epitopes was predicted using the latest
version of NetMHCpan (version 2.8, [38]). Predictions of
strong peptide binders was done by evaluating all pos-
sible eight to eleven-mers from antigens Tp2 and Tp5
with BoLA-6*04101, and BoLA-T5 and BoLA-1*02301
respectively. We also used MHCcluster [39] to compare
predicted peptide-binding specificities between the dif-
ferent BoLA class I molecules involved in this study.
Comparison of sequence similarities between BoLA-T5
and BoLA-1*02301
BoLA-1*02301 and BoLA-T5 amino acid sequences were
downloaded from the Immuno-Polymorphism Database
[40-42] and NCBI respectively, and a MUSCLE alignment
was done using clcSequence Viewer 6.0. Visualization of
the position of the amino acid differences between these
molecules was done on the crystal structure of BoLA-
2*01801 [43] using RasWin.
Results
Generation of peptide-MHC class I tetramers and assay
on defined CTL lines
The “on-demand” Leisner system for tetramer generation
involves p-MHC class I monomer formation in the pres-
ence of excess peptide (concentration of 4 μM), followed
by tetramerization using either PE or APC labelled strep-
tavidin (see Materials and methods). This method was
used to generate a set of seven p-MHC class I tetramers
from recombinant BoLA class I HC and bovine β2m and
synthetic peptides as listed in Table 1. This system does
not routinely measure monomer formation but this be-
came necessary for some experiments (see below).
To verify the specificity of p-MHC class I tetramers we
used T. parva-epitope-specific bulk CTL lines generated
from ECF immune cattle as described in former studies
[28,29,44]. To confirm the epitope specificity of the CTL
lines, an IFN-γ ELISpot assay was performed using the pep-
tides described in Table 1. As expected all CTL lines were
positive in this assay but only in the presence of their re-
spective peptide epitope (data not shown). We then tested
the specificity of the novel BoLA p-MHC class I tetramers
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Tp1214-224-BoLA-6*01301 p-MHC class I tetramer and
BB007 CTL line to control for proper staining (Figure 1).
As negative controls we used unfolded tetramerized HC
(absence of peptides or an irrelevant peptide, Tp296-104,
that does not bind BoLA-6*01301) and tetramerized HC
folded with a control peptide, YMYRVWSPL, known to
bind to BoLA-6*01301. The control peptide was derived
from a bank of random nonamer peptides that bound
with high affinity to BoLA-6*01301 (affinity equal to, or
greater than, 1 nM). As shown, tetramers prepared with
the control peptide (Figure 1B) displayed very low stain-
ing on the CTL when compared to the non-stained
sample (Figure 1A). However, when CTL were stained
with tetramers made without peptide or the irrelevant
peptide we observed a low level smear staining of CTL
(Figure 1C and D respectively), most likely due to non-
specific binding by unfolded HC. When the CTL were
stained with a tetramer formed with the Tp1 peptide
epitope we saw staining of a clear distinct cell popula-
tion (Figure 1E). Figures 1B, C and D suggest that non-Tetramer (PE) + T
A B
C D
Figure 1 Tp1214-224-BoLA-6*01301 p-MHC class I tetramer staining of
(panel A), p-MHC class I tetramers made with the control peptide, YMYRVW
Tp296-104, which is restricted by another BoLA molecule [BoLA-T2c] (panel C
and p-MHC class I tetramers made with peptide Tp1214-224 (panel E). All tetspecific staining of CTL is only observed in the absence
of peptides that bind to HC and that minimal if any
unfolded HC remain when binding peptide is in excess.
Hence, the result in Figure 1E is significant.
Each of the remaining p-MHC class I tetramers was
then tested against the CTL lines, including testing
Tp1214-224-BoLA-6*01301 p-MHC class I tetramers on
a different CTL line, BV115. Distinct tetramer-positive
populations were seen in cognate lines for 6 of the 7 p-
MHC class I tetramers analysed, however, with great
differences in the frequency of tetramer positive cells
between the different cell lines. For example, about 3%
of cell line Bx63 stained positive with Tp8379-387-BoLA-
3*00101 tetramers, while about 65% of cell line 196 stained
positive with Tp296-104-BoLA-T2c tetramers (Figure 2).
Non-specific staining was monitored using unfolded tetra-
mers to differentiate with specific staining (data not shown).
In some cases, p-MHC class I tetramer folded with control
peptides known to bind BoLA-6*01301 and BoLA-3*00101
were used as further controls. The p-MHC class I tetramers
generated with BoLA-T5, BoLA-T2c and BoLA-1*02301etramer (PE) + Tetramer (PE) +
E
bovine CTL line BB007. The CTL line was stained with buffer alone
SPL (panel B), p-MHC class I tetramers made with the peptide
), p-MHC class I tetramers made in the absence of peptide (panel D)
ramers were generated with PE-streptavidin.
AB
C
D
E
F
Control
Control
Control
Control
Control
Control
Tp1214-224+
Tp249-59+
Tp296-104+
Tp587-95+
Tp8 379 - 387 +
Tp967 - 76 +
Tetramer (PE) + Tetramer (PE) +
BV115
592
196
BV50
Bx63
495
Figure 2 Assay of the panel of p-MHC class I tetramers on different antigen specific CTL lines. In each panel the left graph represents
unstained negative control cells and the right graph p-MHC class I tetramer stained cells. Panel A: Tp1214-224-BoLA-6*01301 tetramers on cell line BV115;
Panel B: Tp249-59-BoLA-2*01201tetramers on cell line 592; Panel C: Tp296-104-BoLA-T2c tetramers on cell line Bx196; Panel D: Tp587-95-BoLA-T5 tetramers
on cell line BV50; Panel E: Tp8379-387-BoLA-3*00101 tetramers on cell line Bx63; Panel F: Tp967-76-BoLA-1*02301 tetramers on cell line 495.
All tetramers were generated with PE-streptavidin.
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http://www.veterinaryresearch.org/content/45/1/50were controlled using an irrelevant CTL line to verify that
no nonspecific staining was occurring (data not shown)
since no control peptides for these BoLA molecules were
available. Tp227-37-BoLA-6*04101 p-MHC class I tetramers
did not bind a discrete population of cells in cell line BW02
and resembled a non-specific staining profile (data not
shown). We provide strong evidence below that this is
likely due to Tp229-37 rather than Tp227-37 being the
epitope that binds to BoLA-6*04101 (Figure 3).A role for NetMHCpan in T. parva CTL epitope
identification
We have previously reported that the NetMHCpan algo-
rithm [45] predicted an alternative epitope sequence for
six of the 12 epitopes [30]. Since that time NetMHCpan
has been improved and version 2.8 predicts alternative
epitopes for only 4 of the 12 epitopes: Tp7207-214 instead
of Tp7206-214, Tp241-48 instead of Tp240-48, Tp2138-146 in-
stead of Tp2138-147 and Tp229-37 instead of Tp227-37. As a
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Figure 3 (See legend on next page.)
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Figure 3 Definition of an alternative Tp2 epitope that binds to BoLA-6*04101. Panel A: p-MHC class I monomer formation ELISA assay using
Tp227-37 and Tp229-37 peptides. Panel B: ELISpot performed on two clones (5 and 7) of the cell line BW02 with cell media alone, Tp1214-224, Tp227-
37 or Tp229-37 peptides. Data are presented as spot forming units (SFU) and each well contained 2.5 × 10
4 CTLs. Asterisk (*) indicates saturated
wells. Panel C: Two clones of the cell line BW02 was stained with anti-bovine CD8 (PerCP) and different BoLA-6*04101 tetramers. The unstained
control or stained with the unfolded (no peptide) BoLA-6*04101 tetramer are depicted on the left. Tetramer labelling was measured on the CD8-
gated cell population.
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fraction score. For a given CTL epitope, this score is de-
fined as the number of 8-11mer peptides with a predicted
binding affinity stronger than the epitope divided with the
total number of 8-11mer peptides found within the source
protein sequence. A false positive fraction score closer to
0 is indicative of a high predictive performance.
NetMHCpan predicted that Tp229-37 (EELKKLGML) has
a false positive fraction score of zero for BoLA-6*04101
while that for the peptide Tp227-37 (SHEELKKLGML) we
have been working with (Table 1) was 0.039 (this value has
changed from previous predictions with older version of
NetMHCpan but is still indicative of a low binding affinity
[30]). To experimentally verify this prediction we developed
a semi-quantitative ELISA assay as described in [35] to
measure p-MHC class I monomer formation (see Materials
and Methods). The W6/32 monoclonal antibody used in
the ELISA assay binds to β2m from different species but
only when β2m is in a complex with HC and peptide. If a
stable p-MHC class I complex is not formed, for example
in the absence of peptides, β2m remains free in solution
and will not bind to the streptavidin-bound HC on the
plate. Figure 3A clearly demonstrates that Tp227-37 does
not bind to BoLA-6*04101, whereas Tp229-37 demonstrates
a good binding curve.
We then generated p-MHC class I tetramers made with
each one of the two Tp2 sequences to stain BW02 CTL
line clones that in ELISpot assay respond to both peptide
sequences (Figure 3B). Figure 3C shows a clear difference
in staining profile between the p-MHC class I tetramer
generated with Tp229-37 and the p-MHC class I tetramer
generated with Tp227-37, with the latter showing a profile
similar to that seen for non-specific staining of cells. Thus,
our results strongly support the NetMHCpan prediction
that Tp229-37 and not Tp227-37 is the correct epitope
sequence for BoLA-6*04101.
Tp1-tetramer positive CTL are also positive for CD8, FasL,
and perforin
It has been shown that active CTL express both perforin
and Fas-ligand [1,46,47]. In order to determine if the cells
identified with the tetramers were of the CD8 lineage and
expressed cytotoxicity markers, we performed multiple
staining of cells. For example, all Tp1 positive cells in the
cell line BB007 were CD8-positive (Figure 4A), FasL-
positive (Figure 4B) or perforin-positive (Figure 4C). Atriple staining confirmed that tetramer-positive cells are
also positive for CD8 and perforin (Figure 4D). For the 592,
Bx63 and BV50 CTL cell lines analysed, all tetramer posi-
tive cells were also positive for CD8 but other markers were
not tested (data not shown). We have demonstrated a
correlation between the presence of perforin in tetramer-
positive cells and specific cytotoxic activity in BV115 and
BB007 cell lines as well as from cells isolated ex vivo (data
not shown, manuscript in preparation).
Ex vivo analysis of CTL following ITM vaccination of cattle
With the validation of p-MHC class I tetramers, we wanted
to determine if we could detect antigen specific CTL dir-
ectly isolated from cattle. Three BoLA-A18 positive animals
that were predicted to mount a CTL response to antigen
Tp1 were vaccinated by the ITM method [reviewed in [24]]
using T. parva strain Muguga 3308. Appearance of Tp1
specific CTL in peripheral blood was monitored every two
days following infection using Tp1214-224-BoLA-6*01301
tetramers (Figure 5). As illustrated, Tp1 positive cells were
successfully identified on days 15 to 17 at a frequency of
about 1% of PBMC. The appearance of tetramer-positive
cells correlated with previous reports of cytotoxic activity
towards T. parva peaking at day 18 post-infection [48-50].
Predicted peptide binding specificity as a means of
clustering of the seven BoLA MHC class I molecules
We used the MHCcluster 2.0 server [51] to determine the
functional relationship of the different BoLA class I mole-
cules based on their predicted peptide binding specificities.
According to this analysis BoLA-T5 and BoLA-1*02301
cluster together as depicted in the dendrogram (Figure 6A).
Their similarity in function is more apparent in the
sequence logo of the amino acid motifs predicted to bind
the two BoLA molecules (Figure 6A) and the heat-map
representation of the degree of functional relationship
between the different BoLA molecules (Figure 6B).
The algorithms predicted that the CTL epitope from
Tp5 [87SKADVIAKY95], which was found to be restricted
by BoLA-T5 (Table 1) should also bind BoLA-1*02301
(Figure 7A). This was confirmed by p-MHC monomer
binding assays (data not shown). We then generated
Tp587-95-BoLA-1*02301 p-MHC class I tetramers and
stained BV50 and 495 CTL lines, which are restricted by
BoLA-T5 and BoLA-1*02301, respectively (Table 1). The
only CTL line stained by this tetramer was BV50, which is
Tp
1+
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E)
CD8+ (PerCP)
Perforin+ (FITC)
Fas-ligand+ (FITC)
C
D
8+
 
(P
er
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Tp1+ cells (PE)
DControl
Control
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1+
 (P
E)
Tp
1+
 (P
E)
Perforin+ (FITC)
Control
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B
Figure 4 Multiple staining of Tp1214-224 peptide-MHC tetramer positive cells. In each panel the left graph represents unstained negative
control cells. The cell line BB007 was stained with Tp1214-224-BoLA-6*01301 tetramer in conjunction with anti-bovine CD8 (panel A), anti-Fas-
ligand (panel B), or anti-perforin (panel C). Panel D: BB007 CTL line stained with Tp1214-224-BoLA-6*01301 tetramer and with anti-bovine CD8 and
anti-perforin. Data in Panels A, B and C, and data in Panel D are from two independent experiments.
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http://www.veterinaryresearch.org/content/45/1/50also stained by Tp587-95-BoLA-T5 p-MHC class I tetra-
mers (Figure 7B). Interestingly, both tetramers bind the
same population of CTL as demonstrated by co-staining
of the BV50 cell line with p-MHC class I tetramers using
Tp587-95-BoLA-1*02301 labelled with PE and Tp587-95-
BoLA-T5 labelled with APC. (Figure 7C). A MUSCLE
alignment of the BoLA class I molecules revealed that
there are only 15 amino acid differences between BoLA-
1*02301 and BoLA-T5 (highlighted in Figure 8A by the
amino acid letters in red). The close sequence identity
between these two BoLA class I molecules may explain
their similar peptide binding specificity (Figure 8A).
However, three of the 15 amino acid polymorphisms
map to the peptide binding groove in the α2 domain
(Figure 8B). Nevertheless, our results establish that theTp587-95 epitope can be presented not only by BoLA-T5
but by BoLA-1*02301 as well.Discussion
Peptide-MHC class I tetramer complexes have become
essential tools in cellular immunology to decipher and
characterize epitope-specific CD8+ T cell immune re-
sponses [12,13,21]. They are especially useful for detec-
tion of CTL that occur at low frequency and are finding
many applications in ex vivo assays for direct assess-
ment of T cell responses. Such reagents have become
indispensable tools in murine and human immunology
but are generally lacking for many important livestock
species. In an effort to provide reagents to fill this gap,
Day 8 p.i. Day 16 p.i.
Day 8 p.i. Day 15 p.i.
Day 8 p.i. Day 17 p.i.
Animal 1
Animal 2
Animal 3
Tp
1+
 (P
E)
CD8+ (PerCP)
Figure 5 Identification of Tp1214-224 peptide-MHC tetramer positive cells in ex vivo assays. PBMC were isolated from three BoLA-A18 cattle
vaccinated with the live T. parva (Muguga 3308 strain) and stained with Tp1214-224-BoLA-6*01301 tetramers at day 8 and day 15-17 post infection
(pi). Tetramer labelling was measured on the CD8-gated population.
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http://www.veterinaryresearch.org/content/45/1/50we recently described initial efforts to develop p-MHC
class I tetramers for use in swine and bovine research
[30,34] using a simple in-house system that permits
generation of p-MHC class I tetramers with a turn-
around time of 48 h [11]. Here, we report on p-MHC
class I tetramers made from seven BoLA MHC class Igenes and the power of integrating the on demand
tetramer system with CTL epitope prediction data from
NetMHCpan, a pan specific algorithm, and MHCcluster,
a method for clustering of MHC molecules based on
function, i.e., their predicted peptide binding specific-
ities, rather than sequence.
AB
BoLA-1*02301 BoLA-T5
Figure 6 MHCcluster prediction of the functional similarity of BoLA-T5 and BoLA-1*02301. Panel A: UPGMA tree-based clustering of the
relationship between the seven BoLA molecules (sequence logo representations of the predicted binding motifs of BoLA-T5 and BoLA-1*02301
were generated by MHCcluster using Seq2Logo [52]); Panel B; heat-map visualization of the degree of functional relationship between the seven
BoLA molecules, red colour shows closer functional relationship.
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http://www.veterinaryresearch.org/content/45/1/50We used the novel immunological reagents we generated
to facilitate our research on ECF, a lethal disease of cattle.
Parasite-specific CTL induced by the ITM vaccine play a
major role in mediating immunity to ECF [25,28,29]. A
number of T. parva antigens that are the targets of CTL in-
duced by ITM have been identified using high-throughput
IFN-γ ELISpot immunoscreens of antigen presenting cells
transfected with either candidate T. parva genes or pools of
parasite cDNA libraries [29]. Positive genes were then
tested in cytolytic assays and CTL epitopes mapped by use
of synthetic overlapping peptides. Based on such data a
panel of 12 experimentally verified epitope sequences
derived from seven T. parva antigens and restricted by ten
BoLA class I molecules have been reported [29 and un-
published data]. However, these peptide sequences were
not subjected to systematic analyses to determine minimal
epitope sequence data and due to a lack of appropriatereagents the epitopes were not verified in independent
assays, e.g., in peptide-BoLA binding assays. The prediction
of alternative sequences for some of the CTL epitopes by
NetMHCpan [30] has raised questions regarding the
performance of the algorithm as well as the veracity of
CTL epitope sequences. We have addressed some of these
issues.
The method of Leisner et al. works well for production
of seven recombinant BoLA MHC class I molecules, add-
ing to the list of mammalian MHC molecules generated
by this system. We have made and validated the use of p-
MHC class I tetramers that allow us to rapidly identify T.
parva specific CTL responses directed to one of seven epi-
topes on five different antigens (Figures 1, 2, and 3). We
used these reagents to demonstrate that all Tp1-specific
CTL co-express CD8, FasL or perforin (Figure 4). Such as-
says facilitate rapid typing of the predicted functionality of
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Figure 7 The Tp587-95 epitope is presented by two BoLA molecules (BoLA-T5 and BoLA-1*02301). Panel A: predicted binding affinity of
Tp587-95 peptide epitope for BoLA-1*02301 and BoLA-T5; Panel B: The cell line BV50 stained with anti-bovine CD8 (PerCP) and Tp587-95 p-MHC class I
tetramers made with BoLA-1*02301 or BoLA-T5. Panel C: The cell line BV50 co-stained with anti-bovine CD8 (PerCP), Tp587-95-BoLA-1*02301 tetramers
(PE) and Tp587-95-BoLA-T5 tetramers (APC). Tetramer labelling was measured on the CD8-gated population.
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http://www.veterinaryresearch.org/content/45/1/50T. parva specific CTL. This is important for subunit vaccine
development studies since in the past we have demon-
strated priming of peptide specific IFN-γ ELISpot CD8+ T
cell responses in the absence of cytolytic activity [28], and
only the latter activity correlates with immunity to ECF.
The ability to detect cytolytic activity in peripheral blood
post-vaccination is the range of 14 to 21 days [48-50].
However, several rounds of CTL in vitro stimulation are
required for detection of cytolytic activity. Using the Tp1-
specific tetramer we were able to detect CTL in BoLA-
A18 cattle as early as day 13 post-vaccination by the live
parasite based ITM vaccine (data not shown). The CTLresponse peaked at about day 15 (Figure 5). Thus, the
Tp1-specific tetramers demonstrate high sensitivity and
great potential as diagnostic tools for detecting ECF
immunity in cattle with the ability to stain cells isolated
ex vivo from infected animals without further stimulation
and expansion in vitro. While the remaining p-MHC class
I tetramers remain to be validated in ex vivo assays, we
expect that our collection of p-MHC class I tetramers will
permit studies on the kinetics and functionality of antigen
specific CTL responses to T. parva during infection and
facilitate immunogenicity studies during subunit vaccine
trials. Moreover, as new CTL epitopes restricted by these
A2m
B
3 domain
Peptide in the
binding groove
* * *
Peptide in the
binding groove
2 domain
1 domain 2 domain
1 domain
signal peptide 1 domain
2 domain
3 domain
Figure 8 Sequence alignment of BoLA-T5 and BoLA-1*02301 molecules and identification of amino acid differences in the peptide-
binding groove. Panel A: MUSCLE alignment of BoLA-T5 and BoLA-1*02301 amino acid sequence; differences in amino acid sequence is
highlighted by the red letters; asterisks (*) in red indicate amino acids that map to the pseudo-sequence of 34 amino acids that were defined as
in contact with peptide; sequence highlighted in yellow indicate the signal peptide; sequence highlighted in grey indicate the α1 domain;
sequence highlighted in blue indicate the α2 domain; sequence highlighted in purple indicate the α3 domain. Panel B: Ribbon drawing of the
BoLA-2*01801 [43] molecule with position of all amino acid differences in the α2 (highlighted in blue) and α3 (highlighted in purple) domains
between BoLA-T5 and BoLA-1*02301. Amino acids that map to the pseudo-sequence are illustrated in red; amino acids that do not map to the
pseudo-sequence are illustrated in green. The β2m molecule is illustrated in orange and the peptide in black.
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http://www.veterinaryresearch.org/content/45/1/50BoLA molecules are identified, in future studies we will be
able to rapidly expand the repertoire of p-MHC class I
tetramers available for ECF research.
Several unexpected results were predicted through the
use of NetMHCpan and MHCcluster. The first is that
NetMHCpan predicted that Tp229-37 rather than Tp227-37
is likely to be the correct peptide sequence that binds to
BoLA-6*04101 (Figure 3). The longer Tp2 peptide se-
quence works in both ELISpot and cytolytic assays (our
data and [29]) but this peptide does not bind to BoLA-
6*04101 (Figure 3). We presume that the peptide is proc-
essed to the functional epitope during the ELISpot assays,
which does not occur during the peptide MHC binding
assays or formation of p-MHC class I tetramers.NetMHCpan also predicted three alternative epitopes
from those we have previously described: Tp7207-214 in-
stead of Tp7206-214, Tp241-48 instead of Tp240-48, and
Tp2138-146 instead of Tp2138-147. Due to a lack of CTL
lines of appropriate specificity, we have not been able to
test these predictions. However, Tp7207-214 has been previ-
ously shown to be negative in ELISpot assays [29]. Prelim-
inary data from our group (not shown) has determined a
higher binding affinity of Tp7207-214 for BoLA-T7 (Kd value
of 142 nM) compared to the binding affinity of Tp7206-214
(Kd value of 252 nM). This discrepancy and the alternative
epitopes predicted for Tp2 remains to be resolved.
One of the outputs of the MHCcluster server is a tree-
based (Figure 6A) and heat-map (Figure 6B) visualization
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http://www.veterinaryresearch.org/content/45/1/50of the functional relationship between MHC molecules
based on their predicted peptide binding specificity rather
than sequence alignment of the MHC molecules them-
selves. For example, it is known that HLA-A*0201 and
HLA A*0301 share 93% sequence identity but exhibit com-
pletely different peptide binding specificities [19]. Thus,
clustering on function rather than sequence of MHC mole-
cules is a more important parameter in CTL biology and
immunology. NetMHCpan predicted that the epitope
Tp587-95 should bind to BoLA-1*02301 (with a false posi-
tive fraction of 0.017) in addition to BoLA-T5, the original
molecule that was defined to present the Tp587-95 epitope
by parasite infected cells (Table 1). Using both peptide-
BoLA binding assays and p-MHC class I tetramers we
demonstrate that the Tp587-95 epitope does indeed bind
both BoLA molecules and that a single TCR can recognize
the Tp587-95 epitope presented by either BoLA molecule
(Figure 7). This suggests that as for HLA molecules, it will
be possible to categorize BoLA molecules into supertypes
based on function. More importantly the functional over-
lap of BoLA molecules suggest that it should be possible
to select a repertoire of T. parva antigens to cover a
broader population of cattle than indicted by the limited
specificity of CTL responses generated by the live ITM
vaccine.
The finding that the Tp587-95 epitope binds to two BoLA
molecules was unexpected. What is more surprising was
the observation that three of 15 amino acid sequence
polymorphisms between the BoLA molecules map to the
peptide binding groove (Figure 8B). More specifically they
map to the pseudo-sequence of 34 amino acids in HLA
molecules, which form the basis of the pan prediction cap-
acity of NetMHCpan [37]. These 34 polymorphic residues
have been defined from crystal structure studies as being
within 4.0 Angstrom (Å) of the peptide in any of a repre-
sentative set of HLA-A and HLA-B structures binding a
nonameric peptide [37] and hence are predicted to play a
critical role in peptide binding. Leucine in BoLA-T5 is
replaced by isoleucine in BoLA-1*02301 at position 94;
leucine by alanine at position 96 and arginine by serine at
position 113 in the mature protein (highlighted with red
asterisk in Figure 8A). Of these substitutions two are con-
servative in nature. Our data indicates that these changes
and the non-conservative amino acid substitution do not
have a dramatic influence on the specificity of peptide
binding. The NetMHCpan method has, in several bench-
mark studies, proven to accurately predict the peptide
binding motif for molecules characterised by limited or no
experimental peptide binding data [16,53,54]. In addition,
NetMHCpan can differentiate between critical and less
critical amino acid substitutions in the MHC pseudo-
sequence in situations where the amino acid variations
have been observed and used in training the method [39].
As the training data for NetMHCpan increases it shouldbecome possible to predict such subtleties in peptide bind-
ing to MHC molecules.
An essential feature of the system we have described is
that p-MHC class I tetramers are generated over a 48 h
time frame using an easy protocol starting from the raw in-
gredients of recombinant MHC class I HC, synthetic pep-
tide and recombinant β2m. We have also used the BoLA
molecules to develop a simple ELISA based method to de-
termine peptide-MHC complex formation. The power of
combining such experimental verifications with predictions
from NetMHCpan is highlighted by our results and have
important implications for research on infectious diseases
affecting not only cattle but other animal species including
humans. We have continued to improve NetMHCpan
using peptide-BoLA binding data (manuscript in prepar-
ation) and expect similar improvements to occur through
incorporation of data from other MHC projects. These new
bovine MHC class I tetramers are sensitive tools that can
be used to study the immune responses in cattle e.g. the
CD8+ T cells that play a role in Theileria parva immune
responses or in other parasitic or viral diseases where CTL
contribute to immunity [43,55]. More BoLA class I alleles
could be included in the pipeline as more information
about MHC class I expression in cattle of eastern, central
and southern Africa is generated.
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